Clinical Trial Update: Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update reporting termination of a study evaluating moxetumomab pasudotox in pediatric B-lineage acute lymphoblastic leukemia wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Moxetumomab pasudotox (moxetumomab pasudotox)

Snippet

Sponsor: Center for International Blood and Marrow Transplant Research | Conditions: Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Status: TERMINATED